Ginkgo Bioworks Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.

Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.

Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith...

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is...

BOSTON , Feb. 21, 2025 /PRNewswire/ --  Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow. "I like the Apps and the App Store concept on Callisto.

International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public health preparedness BOSTON , Feb. 20, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration w...

Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ende...